Ken Griffin
PHAT icon

Ken Griffin’s Phathom Pharmaceuticals PHAT Stock Holding History

Ken Griffin’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.73M Buy
515,900
+446,600
+644% +$5.64M ﹤0.01% 4120
2025
Q4 		$1.15M Buy
69,300
+30,900
+80% +$441K ﹤0.01% 7085
2025
Q3 		$452K Sell
38,400
-162,600
-81% -$1.68M ﹤0.01% 9385
2025
Q2 		$1.93M Buy
201,000
+158,900
+377% +$879K ﹤0.01% 5771
2025
Q1 		$264K Buy
42,100
+27,100
+181% +$165K ﹤0.01% 9869
2024
Q4 		$122K Sell
15,000
-3,200
-18% -$39.6K ﹤0.01% 11160
2024
Q3 		$329K Buy
18,200
+15,700
+628% +$219K ﹤0.01% 9139
2024
Q2 		$25.8K Sell
2,500
-16,100
-87% -$166K ﹤0.01% 12414
2024
Q1 		$198K Buy
18,600
+7,500
+68% +$63.7K ﹤0.01% 10336
2023
Q4 		$101K Sell
11,100
-2,800
-20% -$24.1K ﹤0.01% 10925
2023
Q3 		$144K Sell
13,900
-25,100
-64% -$344K ﹤0.01% 10423
2023
Q2 		$558K Sell
39,000
-4,700
-11% -$54.2K ﹤0.01% 7707
2023
Q1 		$312K Buy
43,700
+36,300
+491% +$319K ﹤0.01% 9303
2022
Q4 		$83K Sell
7,400
-85,600
-92% -$882K ﹤0.01% 11471
2022
Q3 		$1.03M Sell
93,000
-3,400
-4% -$32.4K ﹤0.01% 6918
2022
Q2 		$814K Buy
96,400
+40,000
+71% +$411K ﹤0.01% 7500
2022
Q1 		$768K Buy
+56,400
New +$911K ﹤0.01% 8330
2021
Q4 		– Sell
-16,300
Closed -$523K – 14498
2021
Q3 		$523K Buy
+16,300
New +$542K ﹤0.01% 9756

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Ken Griffin's PHAT Position: Q1 2026 in Review

Ken Griffin increased its Phathom Pharmaceuticals (PHAT) stake by 23% in Q1 2026, buying an estimated $906K and bringing the position to 383,058 shares worth $4.26M. The position accounts for ﹤0.01% of the portfolio, ranked #4606.

Ken Griffin first reported a position in PHAT in Q1 2020 and has held it in 21 quarters since. The position peaked at $5.99M in Q3 2025. 174 funds tracked by Wall St. Rank hold PHAT as of Q1 2026.

  • Ken Griffin held 383,058 shares of Phathom Pharmaceuticals worth $4.26M as of Q1 2026.
  • Ken Griffin bought 71,743 Phathom Pharmaceuticals shares in Q1 2026, an estimated $906K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #4606 holding.
  • Ken Griffin first reported a position in Phathom Pharmaceuticals in Q1 2020 and has held it in 21 quarters since.
  • Ken Griffin's Phathom Pharmaceuticals position peaked at $5.99M in Q3 2025.
  • 174 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.